Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Sales (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Return on Sales for 6 consecutive years, with 0.13% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 21.0% year-over-year to 0.13%, compared with a TTM value of 0.0% through Dec 2025, up 27.0%, and an annual FY2025 reading of 0.0%, up 27.0% over the prior year.
  • Return on Sales was 0.13% for Q4 2025 at Xeris Biopharma Holdings, up from 0.01% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.13% in Q4 2025 and bottomed at 3.09% in Q2 2021.
  • Average Return on Sales over 5 years is 0.82%, with a median of 0.43% recorded in 2022.
  • The sharpest move saw Return on Sales plummeted -64bps in 2021, then soared 205bps in 2022.
  • Year by year, Return on Sales stood at 2.34% in 2021, then soared by 83bps to 0.39% in 2022, then increased by 23bps to 0.3% in 2023, then surged by 72bps to 0.09% in 2024, then soared by 252bps to 0.13% in 2025.
  • Business Quant data shows Return on Sales for XERS at 0.13% in Q4 2025, 0.01% in Q3 2025, and 0.03% in Q2 2025.